Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Breast: early-phase trial registry

3 of 6 indexed Breast trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Breast: 6 US clinical trials tracked, 3 recruiting.

Breast is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Wake Forest University Health Sciences, running 2 of these trials.

Enrollment posture brief

Registry condition breast

OPEN 3 | RECR 50% | LATE 0 | EARLY 2 | RANK #2866 | SPON 2

Nearest open-share peer: Achalasia (50% recruiting · 8 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Breast (this)50%
Open-enrollment share among volume-matched conditions near Breast

Breast lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Breast on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Breast is recruiting above its size-band peers.

    3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Breast research.

    Wake Forest University Health Sciences accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Typical Breast enrolment sits around 102 participants.

    Median target enrolment is 102 among the 6 trials that report a genuine target (sentinel values excluded). 3 of those (50%) plan for fewer than 100 participants.

  4. Breast research is mostly interventional.

    5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12

Phase Distribution

PhaseTrial count
Phase 1 2

Named interventions

Most-linked intervention names on Breast records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Standard of Care Vitamin D Dietary supplement
1 trials
High Dose Vitamin D Dietary supplement
1 trials
Open NSM Procedure
1 trials
Robotic NSM Device
1 trials
MEDI4736 Drug
1 trials
Sarilumab 150mg plus Capecitabine Combination
1 trials
Sarilumab 150mg or 200 mg plus Capecitabine Combination
1 trials
pegfilgrastim Drug
1 trials

US sites by state

Facility locations filed on Breast trials. A trial with sites in several states counts in each.

North Carolina 3 trials
Pennsylvania 2 trials
Missouri 2 trials
Michigan 2 trials
Illinois 2 trials
Georgia 2 trials
Florida 2 trials
California 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Breast page

6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast condition card totals 6 registered trials; most-linked intervention Standard of Care Vitamin D; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.